0348 (0348) Fair Value & Analysis

Healthcare · Market cap HK$43.1M

0 0348 0348 · HK

PriceHK$0.0560

Fair ValueHK$0.0582

Upside+4.0%

Quality45/100

Evidence: Medium Range HK$0.0526 – HK$0.0694

Fair value as of: Jul 1, 2026

From 10 valuation models · updated today

Share price −13.8% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.0560 – HK$0.1900 · fair‑value band HK$0.0526 – HK$0.0694 · the HK$0.0560 price screens below the HK$0.0582 fair value. As of Jul 1, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

0348 (0348) currently trades at HK$0.0560, while our model-based Fair Value estimate is HK$0.0582 — implying the stock looks roughly 4.0% undervalued today. We read business quality at 45/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

Over the trailing twelve months, 0348 generated revenue of HK$99.6M at a net margin of -2.6%. Revenue declined 7.9% year over year. Net debt stands at HK$96.9M. Fundamentals as of Jul 1, 2026

Key figures & financial health

Revenue (TTM) HK$99.6M

Revenue growth (YoY) -7.9%

Net margin -2.6%

Return on equity -317%

Free cash flow HK$2.9M FY2026

Operating margin 3.5%

More key figures

Net debt HK$96.9M FY2026

Figures from reported company fundamentals (EODHD) · as of Jul 1, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

0348 reported revenue of HK$99.6M in FY2026 versus HK$170M in FY2022, a compound −12.5%/yr. Reported net income was −HK$2.6M in FY2026.

Revenue −12.5%/yr

FY22 HK$170M

FY23 HK$142M

FY24 HK$146M

FY25 HK$114M

FY26 HK$99.6M

Net income

FY22 −HK$103M

FY23 −HK$54.3M

FY24 −HK$135M

FY25 −HK$40.3M

FY26 −HK$2.6M

Is 0348 fairly valued? → Check now

Similar stocks

6 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Jul 1, 2026).

Stock	Price	Fair Value	vs Fair Value
JD Health International Inc JDHIF	$5.85	$7.13	+22%
Alibaba Health Information Technology Limited ALBBY	$8.27	$6.61	-20%
0241 0241	HK$3.08	HK$2.04	-34%
Raia Drogasil S.A RADL3	R$17.76	R$14.97	-16%
Yifeng Pharmacy Chain Co 603939	¥19.75	¥40.59	+106%
Clicks Group CLCGY	$29.02	$34.57	+19%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 0348 (0348) undervalued?

As of Jul 1, 2026, our model estimates a fair value of HK$0.0582 versus a price of HK$0.0560 — about +4% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 0348?

Our model-based fair value for 0348 is HK$0.0582 (as of Jul 1, 2026), built from audited fundamentals. The current price is HK$0.0560.

What is the quality score of 0348?

0348 has a Quality Score of 45/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 0348 (0348)?

0348 reported trailing-twelve-month revenue of about HK$99.6M (latest available figure, as of Jul 1, 2026).

What is the net profit margin of 0348?

The net profit margin of 0348 is about -2.6%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.